Eli Lilly and (LLY) Earning Somewhat Favorable News Coverage, Report Shows
Press coverage about Eli Lilly and (NYSE:LLY) has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Eli Lilly and earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.086664725781 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:
- Will Azar Practice ‘Art of the Deal’ Capitalism at Trump’s HHS? (finance.yahoo.com)
- Former Eli Lilly Executive Alex Azar Sworn In As Secretary Of Health And Human Services (wfyi.org)
- Lilly (LLY) to Report Q4 Earnings: What's in the Cards? (finance.yahoo.com)
- Alex Azar sworn in as secretary of Health and Human Services (marketbeat.com)
- Eli Lilly and Co. v. Perrigo Co. (jdsupra.com)
LLY has been the topic of a number of research analyst reports. Jefferies Group set a $100.00 price objective on shares of Eli Lilly and and gave the company a “buy” rating in a report on Tuesday, January 16th. Goldman Sachs Group downgraded shares of Eli Lilly and from a “buy” rating to a “neutral” rating and boosted their target price for the company from $86.98 to $95.00 in a research report on Tuesday, January 16th. Argus upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and boosted their target price for the company from $85.52 to $115.00 in a research report on Friday, January 5th. BMO Capital Markets set a $73.00 target price on shares of Eli Lilly and and gave the company a “sell” rating in a research report on Tuesday, December 5th. Finally, Morgan Stanley set a $86.00 price objective on shares of Eli Lilly and and gave the stock a “hold” rating in a research report on Friday, October 6th. Four equities research analysts have rated the stock with a sell rating, six have issued a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $92.41.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be paid a dividend of $0.5625 per share. This represents a $2.25 annualized dividend and a yield of 2.61%. The ex-dividend date is Wednesday, February 14th. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s dividend payout ratio is currently 99.05%.
In other news, SVP Alfonso G. Zulueta sold 2,003 shares of the company’s stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the transaction, the senior vice president now directly owns 43,580 shares in the company, valued at approximately $3,646,338.60. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Susan Mahony sold 36,585 shares of the company’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the completion of the transaction, the senior vice president now owns 54,885 shares in the company, valued at $4,729,989.30. The disclosure for this sale can be found here. In the last three months, insiders sold 251,088 shares of company stock valued at $22,041,236. Corporate insiders own 0.20% of the company’s stock.
WARNING: “Eli Lilly and (LLY) Earning Somewhat Favorable News Coverage, Report Shows” was originally published by Marea Informative and is the property of of Marea Informative. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.mareainformativa.com/2018/01/30/eli-lilly-and-lly-earning-somewhat-favorable-news-coverage-study-finds-updated-updated-updated.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.